Friday, January 27, 2017


Virtualitics Raises $3M For AR/VR/AI Startup
Pasadena-based Virtualitics, a new startup which provides data visualization in virtual reality (VR) and augmented reality (AR) environments, and says it uses machine learning and artificial intelligence, has raised $3M in a seed funding round. The funding came from un-named angel investors. Virtualics said its software is used to provide insights into "big and complex" data. The company's founders are professor George Djorgovski, the founding director of Caltech's Center for Data-Driven Discove (More info...)
posted on Friday, January 27, 2017 (More)(Full story)

Evite Moves Headquarters To Downtown LA
Los Angeles-based online invitations service Evite says it has moved its headquarters to downtown Los Angeles, doubling the size of its corporate office. The company, which previously had its headquarters in West Hollywood, said the move goes to accomodate rapid growth at the company. Evite is part of Liberty Interactive. The company says it has moved to a new office in the 600 Wilshire building. The company did not say how much space is has in the new office, but did say it now has a new "virtu (More info...)
posted on Friday, January 27, 2017(Full story)

STARZ Rolls Out Amazon Fire TV App
Beverly Hills-based entertainment company STARZ, which is part of Lionsgate, said on Thursday afternoon that it has launched a new app on Amazon Fire TV. STARZ said its STARZ App gives users access to all of its original series, plus movies and first run films, on Amazon Fire TV and Fire TV Stick. The app requires an existing subscription to STARZ for accessing that content. STARZ also offers similar apps on Xbox One, Apple TV, iOS, Roku, and Android devices.
posted on Friday, January 27, 2017(Full story)

Amgen Gets European Recommendation For Approval For ABP 501
Thousand Oaks-based biotech Amgen announced this morning that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has given its ABP 501 (Biosilmilar Adalimumab) compouned a positive opinion for treatment of certain inflammatory diseases in adults. The company said the CHMP opinion is the first time an adalimumab biosimilar has been recommended for approval in the EU. The compound is being aimed at treating such conditions as rheumatoid arthritis, pso (More info...)
posted on Friday, January 27, 2017(Full story)